Product
Oral Immunosuppressant
1 clinical trial
1 indication
Indication
Neuromyelitis Optica Spectrum DisorderClinical trial
Effectiveness and Safety of Inebilizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Prospective, Real Word StudyStatus: Not yet recruiting, Estimated PCD: 2025-07-31